Optiscan Imaging (OIL) Q1 2026 TU earnings summary

Executive summary

• Raised $17.75m via a fully underwritten entitlement offer to fund clinical and regulatory activities for three medical devices, strengthening the balance sheet and supporting the next phase of development strategy.

• Imaged the first patient in a breast cancer study at Royal Melbourne Hospital using InVue® and InFormTM devices, with positive initial feedback and further patient recruitment planned.

• Advanced clinical studies in Australia, US, and Germany, including veterinary imaging initiatives and collaborations with Mayo Clinic and University Medical Center Mainz.

• Enhanced product development, including user interface and software upgrades for InVue®, and progressed the next-generation flexible GI endomicroscope project with Capgemini.

• Strengthened commercialisation efforts in the US, China, and Europe, and developed a comprehensive marketing plan for the veterinary device InSpecta™.

• CEO delivered presentations at major industry events, including the ASX SMIDcaps Conference and upcoming Mayo Clinic Beahrs Surgical Innovation Summit.

Financial highlights

• Cash receipts from customers increased to $0.139m for the quarter, up from $0.03m in the previous quarter.

• Net cash used in operating activities decreased to ($2.142m) compared to the prior quarter.

• Cash and cash equivalents at quarter end were $19.99m, up from $4.55m at the previous quarter end.

• Proceeds from equity issuance totaled $17.75m, with transaction costs of $0.07m.

Outlook and guidance

• Focus for the next quarters is on obtaining clinical data to support US FDA regulatory submissions for InVue®, InForm™, and InSpecta™ devices.

• Additional clinical studies are planned both in Australia and internationally, with ongoing engagement with regulatory authorities.

• Pursuing grant funding and non-dilutive funding opportunities to support R&D and clinical activities.